Sign up
Pharma Capital
EPIC: APH
Market: AIM
52-week High/Low: 60.00p / 41.33p
Sector: Pharma & Biotech
Market Cap: 279.84M

Alliance is an international publicly owned pharmaceutical group listed on AIM, part of the London Stock Exchange. It was founded in 1998 and has its headquarters in the UK.

Alliance's principal activities are the acquisition and licensing of mature pharmaceutical products and the marketing of those products. Its manufacturing, storage, logistics and sales forces are controlled by Alliance but outsourced to leading specialist organisations in these fields.

Our expertise lies in the acquisition and licensing of pharmaceutical and healthcare products and delivering these to patients. We look carefully for certain criteria in these products and select for a blend of underlying sales stability and growth potential.

Alliance Pharma plc

www.alliancepharma.co.uk

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Alliance Pharma plc

generic pill and bottle shot to denote Alliance's products
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?

Alliance Pharma plc Snapshot

Vision & Values

Our vision for Alliance Pharma is to breathe life into medicines around the world. We will remain dedicated to patients and continue to serve our shareholders by remaining true to our core values.

 

Performance

Our high performing people continually drive business success.

Realism

We set stretching goals and targets we believe are achievable.

 

Accountability

We take responsibility and deliver what we promise.

Integrity

We build trust in all our relationships through openness and fairness.

 

Skill

We recruit highly skilled people and develop their talents to the full.

Entrepreneurship

Our people think of the business as if it was their own.

Established Products

 

The established products business is our core business. We acquire good, substantial products that continue to meet medical needs. In the UK we have become a leader in the acquisition and management of established products. These products typically grow modestly without active promotion as market demand increases due to changing demographics. The risk of attrition due to competition has usually already occurred or is limited for these products. The value of these product assets is sustained through our ability to keep them up to date and maintain continuity of supply.

 

Having acquired these products’ our team has a unique collection of skills to selectively make medicines better and breathe new life into them. BUCCASTEM, DELTACORTRIL and NU-SEALS are just some of the products that have benefitted from this extra treatment and additional value has been extracted.

 

Depending on the elements of the marketing mix required these products may find their way into our related business units or into partnerships with other players. Whatever the case our aim is to maximise the value of the acquired assets for our shareholders.

 

Products

 

Low and standard dose aspirin with protective coat to help protect against GI side effects of aspirin, low dose is used to prevent heart attacks and ischaemic strokes ,Standard dose used for all aspirin indications except acute pain relief.

 

Gastro-resistant tablets. Used for a wide range of disorders in which systemic corticosteroids are indicated, including allergies, arteritis, rheumatic fever, rheumatic disorders, autoimmune disorders etc.

 

Caps containing 24 essential vits and mins  for use in patients with nutritional deficits, for example in organic diseases such as AIDS, or as a nutritional adjunct following chemotherapy or radiation treatment in conditions where vitamin/mineral absorption is affected such as bowel disease or in the presence of food intolerance.

 

VITAMIN E deficiency in malabsorption disorders.  It is the only UK licensed liquid formulation treatment for the correction of Vitamin E malabsorption in conditions such as including Cystic Fibrosis (CF, primary indication) and chronic cholestasis. The active ingredient is tocopherol acetate, a synthetic form of vitamin E.

 

For a full list of products please click here...

 

Dermatology

 

The Dermatology Business Unit has evolved out of our core established products business and has allowed Alliance to broaden its portfolio through the acquisition of selected dermatological products. These include treatments for eczema, psoriasis, ichthyosis, acne, warts and irritated skin.

 

The acquisition and subsequent promotion of the Hydromol range has proved particularly successful with sales tripling over the last 4 years. The HYDROMOL Range consists of HYDROMOL Bath and Shower Emollient, HYDROMOL Cream, HYDROMOL Ointment and HYDROMOL Intensive.

 

Further information can be found on the HYDROMOL website www.hydromol.co.uk

 

The addition of TIMODINE to the dermatology business in 2009 is an example of Alliance’s continued ambition to expand its portfolio and establish itself in the dermatology market.

 

 

International 

 

Alliance aims to grow its business rapidly through International expansion. We are currently in the process of establishing affiliates throughout Europe. These affiliates will be growing their businesses through the acquisition and licensing of mature pharmaceutical products, medical devices, OTCs and the marketing of those products. Key international markets are China, the Republic of Ireland, France and Germany.

 

In addition we sell our products in over 25 territories. Key international brands are NU-SEALS and FORCEVAL. The International business has grown historically through acquisitions of business and products and the development of a network of distributors.

 

Secondary Care

 

With a specialist business unit focused on the promotion and supply of specialist secondary care (hospital) medicines, Alliance provides full and direct key account coverage to hospitals across the UK, specifically in the therapeutic areas of urology and oncology.

 

These products include the BCG immunotherapy brand IMMUCYST 81MG, which is for the treatment of non invasive bladder cancer. Non muscle invasive bladder cancer accounts for 70% of diagnosed bladder cancer in the UK.

 

Other products include GELCLAIR, for the management of chemotherapy and radiotherapy induced oral mucositis, a painful and debilitating side effect of cancer treatments.

 

Further information can be found on the GELCLAIR website www.gelclair.co.uk

Andrew Smith, Chairman

Andrew joined the Board of Alliance in 2006. He has held various senior positions in the pharmaceutical industry in the UK and USA having been Managing Director and Senior Vice-President of SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), Chief Executive of Cerebrus plc until its sale, and President of International Medical Marketing Services with Parexel International. Andrew is a  founder of Navitas BioPharma Consulting. He graduated in Natural Sciences from the University of Cambridge.

John Dawson, Chief Executive Officer

John founded Alliance in 1996. He gained multi-disciplinary experience in the pharmaceutical industry over 30 years. John held various senior roles at Sandoz (now Novartis AG) as Director of Finance and Administration and Deputy Managing Director. John has a BSc (Pharmacy) and an MSc (Finance) from the London Business School.

Peter Butterfield, Executive Director

Peter joined the board of Alliance in February 2010 following the acquisition of Cambridge Laboratories, where he spent five years, latterly as UK Commercial Director. With over 17 years industry experience, he has also served as a Board Member of the Association of the British Pharmaceutical Industry ("ABPI"). Prior to joining Cambridge Laboratories, Peter spent six years at GlaxoSmithKline. He holds an honours degree in Pharmacology from the University of Edinburgh.

Thomas Casdagli, Non-Executive Director

Thomas joined the board of Alliance as a Non-Executive Director on 3 March 2009. He is a partner at MVM Life Science Partners LLP, a life science venture capital fund. He has been an active investor in life sciences since joining MVM in 2002. Before joining MVM, Thomas worked at PricewaterhouseCoopers LLP where he qualified as a Chartered Accountant. Thomas graduated in Molecular and Cellular Biochemistry from the University of Oxford in 1998.

Nigel Clifford, Non-Executive Director

Nigel joined the board of Alliance as a Non-Executive Director on 26 January 2015. He is currently Chief Executive at Ordnance Survey having been previously Chief Executive of Procserve Holdings Limited. He is also currently a Non-Executive Director of Anite plc. He has previously held senior positions at Micro Focus International plc, Nokia, Symbian Software Ltd, Tertio Telecoms Limited, Cable and Wireless plc, Glasgow Royal Infirmary NHS Trust and BT plc. Nigel graduated in Geography from the University of Cambridge and has an MBA from Strathclyde University.

David Cook, Non-Executive Director

David joined the Board of Alliance in April 2014. He was most recently Chief Financial Officer and Chief Business Officer of Biotie Therapies Corp., a drug development copany quoted in Helsinki on the NASDAQ QMX market and in New York on NASDAQ. He has previously held senior financial positions with Jazz Pharmaceuticals Limited, EUSA Pharma Inc., and Zeneus Pharma. David qualified as a Chartered Accountant with PricewaterhouseCoopers after graduating in Chemistry at the University of Oxford.

Andrew Franklin, Chief Financial Officer

Andrew joined the board of Alliance on the 28 September 2015 following his appointment as Chief Financial Officer. From 2010 to 2012, Andrew was Finance Director and Company Secretary of Genzyme Therapeutics Ltd.  Prior to that, he gained 12 years’ pharmaceutical experience with Wyeth in a variety of senior financial positions.  Andrew joins Alliance from Panasonic Europe Ltd, where he was General Manager, European Tax and Accounting. He qualified as a Chartered Accountant with Arthur Andersen in 1992 having graduated with an honours degree in Civil Engineering from the University of Wales, Cardiff in 1988.

Major Shareholders

Shares in Issue: 474,307,589 p Ords
Last updated: 12 June 2017

Major Shareholders Amount % Holding
MVM Life Science Partners 55,561,900 11.74
Artemis Fund Managers Ltd 47,785,954 10.09
Fidelity Management & Research 44,484,566 9.40
Slater Investments 34,635,000 7.32
Nigel Wray 24,935,857 5.27
River & Mercantile Asset Management 23,870,000 4.83
GVQ Investment Management Ltd 22,450,000 4.74
John Dawson (beneficial) 21,000,079 4.43
John Dawson (non beneficial) 20,000,000 4.22
Stella Dawson 15,576,323 3.2

 

Alliance Pharma plc
Avonbridge House
Bath Road
Chippenham
Wiltshire SN15 2BB
United Kingdom

Telephone +44 [0]1249 466966
Fax +44 [0]1249 466977
Email [email protected]
Email [email protected]


Pharmacovigilance:
[email protected]

Investor Relations:
[email protected]

Business Development:
[email protected]

International:
[email protected]

Careers:
[email protected]

Corporate Advisors


Broker & Nominated Advisor: Numis Securities


Bank: Lloyds Bank and Royal Bank of Scotland and Silicon Valley Bank


Auditor: KPMG LLP


Financial PR: Buchanan Communications

 

Registrars:

Capita Registrars 

The Registry

34 Beckenham Road

Beckenham

Kent

BR3 4TU

Alliance Pharma plc Timeline

View All

Market Reports Including APH

VIEW ALL

Executive video interviews

VIEW ALL VIDEOS

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.